AAAAAA

   
Results: 1-16 |
Results: 16
COMPARISON OF 5-FLUOROURACIL PHARMACOKINETICS IN PATIENTS RECEIVING CONTINUOUS 5-FLUOROURACIL INFUSION AND ORAL URACIL PLUS N-1-(2'-TETRAHYDROFURYL)-5-FLUOROURACIL
Authors: HO DH PAZDUR R COVINGTON W BROWN N HUO YY LASSERE Y KURITANI J
Citation: Dh. Ho et al., COMPARISON OF 5-FLUOROURACIL PHARMACOKINETICS IN PATIENTS RECEIVING CONTINUOUS 5-FLUOROURACIL INFUSION AND ORAL URACIL PLUS N-1-(2'-TETRAHYDROFURYL)-5-FLUOROURACIL, Clinical cancer research, 4(9), 1998, pp. 2085-2088
PHASE-I TRIAL OF URACIL-TEGAFUR (UFT) PLUS ORAL LEUCOVORIN - 28-DAY SCHEDULE
Authors: PAZDUR R LASSERE Y DIAZCANTON E HO DH
Citation: R. Pazdur et al., PHASE-I TRIAL OF URACIL-TEGAFUR (UFT) PLUS ORAL LEUCOVORIN - 28-DAY SCHEDULE, Cancer investigation, 16(3), 1998, pp. 145-151
A BINDING-SITE FOR HEPARIN IN THE APPLE-3 DOMAIN OF FACTOR-XI
Authors: HO DH BADELLINO K BAGLIA FA WALSH PN
Citation: Dh. Ho et al., A BINDING-SITE FOR HEPARIN IN THE APPLE-3 DOMAIN OF FACTOR-XI, The Journal of biological chemistry, 273(26), 1998, pp. 16382-16390
PSYCHOGENIC POLYDIPSIA AFTER TRAUMATIC BRAIN INJURY - A CASE-REPORT
Authors: ZAFONTE RD WATANABE TK MANN NR HO DH
Citation: Rd. Zafonte et al., PSYCHOGENIC POLYDIPSIA AFTER TRAUMATIC BRAIN INJURY - A CASE-REPORT, American journal of physical medicine & rehabilitation, 76(3), 1997, pp. 246-248
IN-VITRO ACTIVITY OF TROVAFLOXACIN AGAINST CLINICAL BACTERIAL ISOLATES FROM PATIENTS WITH CANCER
Authors: ROLSTON KVI HO DH LEBLANC B STREETER H DVORAK T
Citation: Kvi. Rolston et al., IN-VITRO ACTIVITY OF TROVAFLOXACIN AGAINST CLINICAL BACTERIAL ISOLATES FROM PATIENTS WITH CANCER, Journal of antimicrobial chemotherapy, 39, 1997, pp. 15-22
PHASE-I TRIAL OF URACIL-TEGAFUR (UFT) PLUS ORAL LEUCOVORIN - 14-DAY SCHEDULE
Authors: PAZDUR R LASSERE Y DIAZCANTON E BREADY B HO DH
Citation: R. Pazdur et al., PHASE-I TRIAL OF URACIL-TEGAFUR (UFT) PLUS ORAL LEUCOVORIN - 14-DAY SCHEDULE, Investigational new drugs, 15(2), 1997, pp. 123-128
PHASE-I TRIALS OF URACIL-TEGAFUR (UFT) USING 5 AND 28 DAY ADMINISTRATION SCHEDULES - DEMONSTRATION OF SCHEDULE-DEPENDENT TOXICITIES
Authors: PAZDUR R LASSERE Y DIAZCANTON E BREADY B HO DH
Citation: R. Pazdur et al., PHASE-I TRIALS OF URACIL-TEGAFUR (UFT) USING 5 AND 28 DAY ADMINISTRATION SCHEDULES - DEMONSTRATION OF SCHEDULE-DEPENDENT TOXICITIES, Anti-cancer drugs, 7(7), 1996, pp. 728-733
A PHASE-I AND PHARMACOKINETIC STUDY OF ORAL URACIL, FTORAFUR, AND LEUCOVORIN IN PATIENTS WITH ADVANCED CANCER
Authors: MEROPOL NJ RUSTUM YM PETRELLI NJ RODRIGUEZBIGAS M FRANK C HO DH KUROWSKI M CREAVEN PJ
Citation: Nj. Meropol et al., A PHASE-I AND PHARMACOKINETIC STUDY OF ORAL URACIL, FTORAFUR, AND LEUCOVORIN IN PATIENTS WITH ADVANCED CANCER, Cancer chemotherapy and pharmacology, 37(6), 1996, pp. 581-586
IN-VITRO ACTIVITY OF RAMOPLANIN (A NOVEL LIPOGLYCOPEPTIDE), VANCOMYCIN, AND TEICOPLANIN AGAINST GRAM-POSITIVE CLINICAL ISOLATES FROM CANCER-PATIENTS
Authors: ROLSTON KVI DHOLAKIA N HO DH LEBLANC B DVORAK T STREETER H
Citation: Kvi. Rolston et al., IN-VITRO ACTIVITY OF RAMOPLANIN (A NOVEL LIPOGLYCOPEPTIDE), VANCOMYCIN, AND TEICOPLANIN AGAINST GRAM-POSITIVE CLINICAL ISOLATES FROM CANCER-PATIENTS, Journal of antimicrobial chemotherapy, 38(2), 1996, pp. 265-269
IDENTIFICATION OF CONTIGUOUS AND DISTINCT BINDING-SITES FOR PLATELETSAND HEPARIN IN THE APPLE-3 DOMAIN OF COAGULATION-FACTOR-XI
Authors: HO DH BAGLIA FA WALSH PN
Citation: Dh. Ho et al., IDENTIFICATION OF CONTIGUOUS AND DISTINCT BINDING-SITES FOR PLATELETSAND HEPARIN IN THE APPLE-3 DOMAIN OF COAGULATION-FACTOR-XI, Blood, 88(10), 1996, pp. 1120-1120
NORMOCALCEMIC EFFECT OF GALLIUM NITRATE IN A HYPERCALCEMIC RAT MODEL
Authors: LIN JR BEKERSKY I BROWN NS MONG S LEE F NEWMAN RA HO DH
Citation: Jr. Lin et al., NORMOCALCEMIC EFFECT OF GALLIUM NITRATE IN A HYPERCALCEMIC RAT MODEL, Cancer research, 55(2), 1995, pp. 307-311
IN-VITRO ACTIVITY OF FK-037, A NOVEL PARENTERAL CEPHALOSPORIN, AGAINST BACTERIAL ISOLATES FROM NEUTROPENIC CANCER-PATIENTS
Authors: DHOLAKIA N ROLSTON KVI HO DH LEBLANC B STREETER H DVORAK T BODEY GP
Citation: N. Dholakia et al., IN-VITRO ACTIVITY OF FK-037, A NOVEL PARENTERAL CEPHALOSPORIN, AGAINST BACTERIAL ISOLATES FROM NEUTROPENIC CANCER-PATIENTS, European journal of clinical microbiology & infectious diseases, 13(8), 1994, pp. 679-685
DETERMINATION OF PEPLOMYCIN IN MOUSE-TISSUES AND BIOFLUIDS BY RADIOIMMUNOASSAY
Authors: LIN JR BROWN NS NEWMAN RA HO DH
Citation: Jr. Lin et al., DETERMINATION OF PEPLOMYCIN IN MOUSE-TISSUES AND BIOFLUIDS BY RADIOIMMUNOASSAY, Journal of pharmaceutical and biomedical analysis, 12(2), 1994, pp. 145-150
DEPLETION OF PATIENTS PLASMA TRYPTOPHAN USING TRYPTOPHAN SIDE-CHAIN OXIDASE COLUMNS
Authors: HO DH COVINGTON WP WALLERSTEIN RO HESTER JP LIN JR BROWN NS NEWMAN RA KRAKOFF IH FREIREICH EJ
Citation: Dh. Ho et al., DEPLETION OF PATIENTS PLASMA TRYPTOPHAN USING TRYPTOPHAN SIDE-CHAIN OXIDASE COLUMNS, Cancer investigation, 11(3), 1993, pp. 252-257
CLINICAL-PHARMACOLOGY OF MOYLOXYMETHYL-4-FORMYL-14-OXA-1,11-DIAZATETRACYCLO (7.4.1.0(2,7).0(10,12)) TETRADECA-2,4,6-TRIEN-6,9-DIYL DIACETATE (FK-973)
Authors: HO DH PAZDUR R BROWN NS COVINGTON WP RABER MN KRAKOFF IH
Citation: Dh. Ho et al., CLINICAL-PHARMACOLOGY OF MOYLOXYMETHYL-4-FORMYL-14-OXA-1,11-DIAZATETRACYCLO (7.4.1.0(2,7).0(10,12)) TETRADECA-2,4,6-TRIEN-6,9-DIYL DIACETATE (FK-973), Anticancer research, 13(2), 1993, pp. 343-346
IN-VITRO ACTIVITIES OF ANTIMICROBIAL AGENTS AGAINST CLINICAL ISOLATESOF FLAVIMONAS-ORYZIHABITANS OBTAINED FROM PATIENTS WITH CANCER
Authors: ROLSTON KVI HO DH LEBLANC B BODEY GP
Citation: Kvi. Rolston et al., IN-VITRO ACTIVITIES OF ANTIMICROBIAL AGENTS AGAINST CLINICAL ISOLATESOF FLAVIMONAS-ORYZIHABITANS OBTAINED FROM PATIENTS WITH CANCER, Antimicrobial agents and chemotherapy, 37(11), 1993, pp. 2504-2505
Risultati: 1-16 |